
In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia
THE POWER TO PREVENT RISING URIC
ACID LEVELS IS IN YOUR HANDS

In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia
THE POWER TO PREVENT RISING URIC
ACID LEVELS IS IN YOUR HANDS
In a phase 3 trial, ELITEK given prophylactically (prior to anticancer therapy) maintained normal uric acid levels (≤7.5 mg/dL) in significantly more patients (87%, n=92) vs allopurinol (66%, n=91) between 3 and 7 days after initiation of antihyperuricemic treatment (P=0.001) (primary endpoint).1


IDENTIFY
patients at risk
Find out what your peers are saying about patients at higher risk for TLS
SEE TLS RISK FACTORS




CAREASSIST PROGRAM
Find resources and support for eligible patients
access and reimbursement
Assistance navigating the insurance process, including benefits investigations, claims assistance, and information about prior authorizations and appeals.
financial assistance
CareASSIST offers programs and services that can help eligible patients with the cost of ELITEK.
resource support
Information on independent support services for patients and caregivers, as well as product ordering and replacement information.
Reference: 1. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213.